BeOne Medicines (SS:688235) announced Wednesday that the U.S. Food and Drug Administration has approved its therapy Beqalzi for patients with relapsed or refractory mantle cell lymphoma, an aggressive malignancy of the lymphatic system that affects certain disease-fighting white blood cells and either returns after initial therapy or does not respond to it.
The agency granted accelerated approval following evaluation of data from an early-to-mid-stage clinical study. In that trial, Beqalzi produced complete responses - defined as the disappearance of all detectable signs of cancer - in 16% of treated patients.
A company spokesperson said Beqalzi is expected to reach the U.S. market in the second half of this year.
BeOne described Beqalzi as a targeted agent that inhibits the BCL2 protein, a key survival factor for certain blood cancers. The company said the drug delivers stronger and more precise BCL2 blockade, with the potential to improve efficacy while offering a safer and easier experience for patients to take.
According to BeOne, Beqalzi is the first BCL-2 inhibitor in its class to receive approval specifically for mantle cell lymphoma. Other BCL-2 inhibitors, such as Venclexta marketed by AbbVie (NYSE:ABBV) and Roche (SIX:ROPC), are approved for other blood cancer indications but not for mantle cell lymphoma.
In the U.S., a range of therapies are approved for mantle cell lymphoma. BeOne listed currently approved options as Takeda’s (TSE:4502) Velcade, Bristol Myers’ (NYSE:BMY) Revlimid and Breyanzi, BeOne’s Brukinsa, Lilly’s (NYSE:LLY) Jaypirca and Gilead’s (NASDAQ:GILD) Tecartus.
BeOne also noted that approximately 3,300 new cases of mantle cell lymphoma are diagnosed annually in the United States.
Key points
- FDA granted accelerated approval to Beqalzi for relapsed or refractory mantle cell lymphoma based on early-to-mid-stage trial data showing a 16% complete response rate.
- Beqalzi targets the BCL2 survival protein and is described by BeOne as a stronger, more precise inhibitor with potential safety and patient convenience benefits.
- The drug is slated to launch in the U.S. in the second half of the year; mantle cell lymphoma has about 3,300 new U.S. diagnoses annually, per the company.
Risks and uncertainties
- The FDA approval was granted under the accelerated pathway and relied on early-to-mid-stage clinical data, which implies further confirmatory evidence may be required.
- The observed complete response rate in the supporting study was 16%, indicating that the majority of treated patients did not achieve complete disappearance of detectable disease in that trial.
- Beqalzi will enter a market with multiple existing approved therapies for mantle cell lymphoma, which may affect uptake and positioning.
This report presents the facts released by the company and the regulatory action by the FDA without additional interpretation beyond the stated information.